Effect of Pentoxifylline on Anemia in Hemodialysis Patients
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The primary goal of this clinical trial is to evaluate the promoting effect of pentoxifylline
on anemia correction in hemodialysis patients, and involvement of the hypoxia-inducible
factor-2 alpha. While, the secondary aim is to evaluate the effect of pentoxifylline on
inflammation, hepcidin and other markers of iron homeostasis in these patients. Participants
in this trial will be selected to be age and sex ratio matched and will be randomly assigned
into two groups. Patients in group I will receive their regular doses of erythropoietin
stimulating agents and other routine treatments plus 400 mg pentoxifylline tablets twice
daily with meals for 6 months. While, patients in group II will receive their regular doses
of erythropoietin stimulating agents and other routine treatments.